Taihao Medical

About Taihao Medical

Taihao Medical designs and develops AI medical software to help healthcare providers manage the increasing workloads. We focus on breast screening & diagnostic solution by utilizing ultrasound and LDCT AI solutions for lung disease. Our leading products include: 1.BR-FHUSTM Smart System (Free-Hand ABUS): AI for ultrasound breast screening 2.BR-ViewerTM for ABUS 3.BU-CADTM Decision Support: AI for ultrasound breast cancer diagnosis 4.Ti–LUNGTM Decision Support: AI for LDCT lung cancer screening & diagnosis Leading technology & expertise include: 1.Real-Time AI detects suspicious areas in Ultrasound images 2.Advisory Board include scientists & physicians in Taiwan, Japan, China, and USA We have received US FDA, Japan's PMDA, Taiwan's TFDA, China's NMPA, and more than 10 patent licenses. We not only advocate our products to the world, integrate with AI marketplace, but also cooperate with government’s screening program, women breast centers, mammography clinics, insurance companies and ultrasound machine manufacturers. Taihao Medical’s shareholders include CDIB Capital Healthcare Ventures Limited, Japan ＣＥＳデカルト, Top Taiwan Venture Capital Co., Ltd. and CTBC Securities Venture Capital Co., Ltd., who are involved in our capital investing. We strive for integrating our AI products in different types of ultrasound devices. Furthermore, global market expansion has been one of our key landmarks for the past and upcoming years, supported by our strong technical team in related areas. They are highly professional and well experienced. “Early Detection, Early Treatment, Most Lives Saved” is Taihao’s Value Proposition. We aim to be one of the most successful AI Medical companies worldwide. Welcome to follow our Linkedin and notice our continuous milestone, the latest news, and employees' life in Taihao Medical.

View contact profiles from Taihao Medical